Research advances in clinical treatment of adult autoimmune hepatitis

Mingyue ZHANG; Lin HAN; Ying SUN; Zhengsheng ZOU

doi:10.3969/j.issn.1001-5256.2021.06.050

Volume 37 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(6): 1459-1465

PDF( 2843 KB)

Research advances in clinical treatment of adult autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2021.06.050

Mingyue ZHANG^{1, 2},
Lin HAN²,
Ying SUN^{2
,
,},
Zhengsheng ZOU^{2
,
,}

1.
Graduate School, Medical School of Chinese PLA, Beijing 100039, China
2.
Department of Hepatology, Division of Liver Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Received Date: 2020-11-24
Accepted Date: 2020-12-25
Published Date: 2021-06-20

Abstract

Abstract

Autoimmune hepatitis (AIH) is an immune-mediated inflammatory injury of hepatocytes, which can develop into liver cirrhosis and end-stage liver disease. Timely immunosuppressive therapy can help patients achieve biochemical remission and even histological remission and thus improve prognosis. However, adverse drug reactions during treatment and recurrence after withdrawal are commonly seen, and therefore, standard therapy, dose reduction at the right time, and timely drug withdrawal are important for improving patients' prognosis. This article summarizes the advances in guidelines for the diagnosis and treatment of AIH and related studies in China and globally, so as to provide a reference for clinicians in the treatment of AIH.
- Hepatitis, Autoimmune,
- Adult,
- Therapeutics

FullText(HTML)

References(31)

References

[1]	DANZIGER-ISAKOV L, KUMAR D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13563. DOI: 10.1111/ctr.13563.
[2]	LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
[3]	TERRAULT NA, LOK A, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[4]	REDDY KR, BEAVERS KL, HAMMOND SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology, 2015, 148(1): 215-219. DOI: 10.1053/j.gastro.2014.10.039.
[5]	PERRILLO RP, GISH R, FALCK-YTTER YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J]. Gastroenterology, 2015, 148(1): 221-244. DOI: 10.1053/j.gastro.2014.10.038.
[6]	PATTULLO V. Prevention of hepatitis B reactivation in the setting of immunosuppression[J]. Clin Mol Hepatol, 2016, 22(2): 219-237. DOI: 10.3350/cmh.2016.0024.
[7]	EBADI M, BHANJI RA, MAZURAK VC, et al. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2019, 49(2): 173-182. DOI: 10.1111/apt.15029.
[8]	CZAJA AJ, MONTANO-LOZA AJ. Evolving role of vitamin D in immune-mediated disease and its implications in autoimmune hepatitis[J]. Dig Dis Sci, 2019, 64(2): 324-344. DOI: 10.1007/s10620-018-5351-6.
[9]	American Gastroenterological Association. American Gastroenterological Association medical position statement: Osteoporosis in hepatic disorders[J]. Gastroenterology, 2003, 125(3): 937-940. DOI: 10.1016/s0016-5085(03)01060-6.
[10]	JANIK MK, WUNSCH E, RASZEJA-WYSZOMIRSKA J, et al. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study[J]. Liver Int, 2019, 39(1): 215-221. DOI: 10.1111/liv.13960.
[11]	MIELI-VERGANI G, VERGANI D, CZAJA AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18017. DOI: 10.1038/nrdp.2018.17.
[12]	WONG LL, FISHER HF, STOCKEN DD, et al. The impact of autoimmune hepatitis and its treatment on health utility[J]. Hepatology, 2018, 68(4): 1487-1497. DOI: 10.1002/hep.30031.
[13]	SHEIKO MA, SUNDARAM SS, CAPOCELLI KE, et al. Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites[J]. J Pediatr Gastroenterol Nutr, 2017, 65(1): 80-85. DOI: 10.1097/MPG.0000000000001563.
[14]	MANNS MP, WOYNAROWSKI M, KREISEL W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J]. Gastroenterology, 2010, 139(4): 1198-1206. DOI: 10.1053/j.gastro.2010.06.046.
[15]	HEMPFLING W, GRUNHAGE F, DILGER K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis[J]. Hepatology, 2003, 38(1): 196-202. DOI: 10.1053/jhep.2003.50266.
[16]	PEISELER M, LIEBSCHER T, SEBODE M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 260-267. DOI: 10.1016/j.cgh.2016.12.040.
[17]	ZACHOU K, GATSELIS NK, ARVANITI P, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2016, 43(10): 1035-1047. DOI: 10.1111/apt.13584.
[18]	NASTASIO S, SCIVERES M, MATARAZZO L, et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis, 2019, 51(5): 712-718. DOI: 10.1016/j.dld.2018.10.018.
[19]	VAN THIEL DH, WRIGHT H, CARROLL P, et al. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial[J]. Am J Gastroenterol, 1995, 90(5): 771-776.
[20]	RAHIM MN, LIBERAL R, MIQUEL R, et al. Acute severe autoimmune hepatitis: Corticosteroids or liver transplantation?[J]. Liver Transpl, 2019, 25(6): 946-959. DOI: 10.1002/lt.25451.
[21]	CZAJA AJ, CARPENTER HA. Autoimmune hepatitis overlap syndromes and liver pathology[J]. Gastroenterol Clin North Am, 2017, 46(2): 345-364. DOI: 10.1016/j.gtc.2017.01.008.
[22]	KUIPER EM, ZONDERVAN PE, van BUUREN HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome[J]. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534. DOI: 10.1016/j.cgh.2010.03.004.
[23]	TRAN TT, AHN J, REAU NS. Corrigendum: ACG Clinical Guideline: Liver disease and pregnancy[J]. Am J Gastroenterol, 2016, 111(11): 1668. DOI: 10.1038/ajg.2016.462.
[24]	AKBARI M, SHAH S, VELAYOS FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19(1): 15-22. DOI: 10.1002/ibd.22948.
[25]	COSCIA LA, ARMENTI DP, KING RW, et al. Update on the teratogenicity of maternal mycophenolate mofetil[J]. J Pediatr Genet, 2015, 4(2): 42-55. DOI: 10.1055/s-0035-1556743.
[26]	TAUBERT R, HARDTKE-WOLENSKI M, NOYAN F, et al. Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis[J]. PLoS One, 2017, 12(6): e0179074. DOI: 10.1371/journal.pone.0179074.
[27]	HARTL J, EHLKEN H, WEILER-NORMANN C, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis[J]. J Hepatol, 2015, 62(3): 642-646. DOI: 10.1016/j.jhep.2014.10.018.
[28]	GUIRGUIS J, ALONSO Y, LOPEZ R, et al. Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance[J]. Gastroenterol Rep (Oxf), 2018, 6(4): 284-290. DOI: 10.1093/gastro/goy020.
[29]	THAN NN, WIEGARD C, WEILER-NORMANN C, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy[J]. Scand J Gastroenterol, 2016, 51(3): 329-336. DOI: 10.3109/00365521.2015.1095351.
[30]	HVBENER S, OO YH, THAN NN, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance[J]. Clin Gastroenterol Hepatol, 2016, 14(3): 445-453. DOI: 10.1016/j.cgh.2015.09.037.
[31]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (800) PDF downloads(83)

Research advances in clinical treatment of adult autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2021.06.050

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in clinical treatment of adult autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2021.06.050

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content